Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
NPCE
#2547
Neuropace, Inc. Common Stock
14.580
0
-0.95%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-0.95%
Variazione Mensile
-9.97%
Variazione di 6 mesi
+37.81%
Variazione Annuale
+37.81%
Chiusura Precedente
14.720
0
Open
14.580
0
Bid
Ask
Low
14.580
0
High
14.580
0
Volume
30
Mercati
Mercato Azionario Statunitense
Salute
NPCE
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
29.85 M
32.56 M
32.8 M
33.08 M
33.31 M
—
Valuation ratios
Enterprise value
192.62 M
350.92 M
376.07 M
345.67 M
322.75 M
1.4 B
Price to earnings ratio
-7.04
-12.03
-14.99
-13.59
-13.93
-54.54
Price to sales ratio
2.54
4.08
4.3
3.82
3.41
15.61
Price to cash flow ratio
-11.78
-18.16
-20.53
-21.14
-19.56
-79.39
Price to book ratio
3.5
40.67
7.09
5.6
4.64
58.01
Enterprise value to EBITDA ratio
-8.52
-16.52
-19.93
-17.76
-18.14
-72.34
Profitability ratios
Return on assets %
0.06
0.06
0.06
0.08
0.03
0.23
Return on equity %
0.56
0.66
0.27
0.45
0.19
1.56
Return on invested capital %
60.48
—
67.6
88.98
34.72
—
Gross margin %
73.22
75.41
76.99
77.09
77.39
306.88
Operating margin %
20.15
17.02
22.85
29.01
9.51
78.39
EBITDA margin %
-19.45
-17
-22.42
-28.35
-8.88
-76.65
Net margin %
25.89
24.46
29.25
36.78
12.78
103.27
Liquidity ratios
Quick ratio
4.77
4.48
5.7
4.51
3.94
18.64
Current ratio
5.59
5.37
6.63
5.47
4.86
22.33
Inventory turnover
0.48
0.41
0.38
0.36
0.36
1.52
Asset turnover
0.22
0.22
0.22
0.22
0.26
0.92
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.62
0.63
0.54
0.55
0.55
2.27
Long term debt to total equity ratio
6.03
7.43
2.46
3.02
3.17
16.08
Per share metrics
Operating cash flow per share
0.06
0.16
0.24
0.06
0.06
0.52
EBIT per share
-0.14
-0.13
-0.16
-0.21
-0.08
-0.58
EBITDA per share
-0.14
-0.13
-0.16
-0.2
-0.07
-0.56
Total debt per share
—
—
—
—
—
—
Cash per share
1.93
1.81
2.11
1.89
1.81
7.62
Net current asset value per share
2.8
2.79
3.1
2.85
2.88
11.62
Tangible book value per share
0.33
0.28
0.77
0.59
0.56
2.2
Working capital per share
2.3
2.27
2.63
2.33
2.29
9.52
Book value per share
0.33
0.28
0.77
0.59
0.56
2.2
Notizie
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Obiettivo di prezzo per le azioni NeuroPace alzato a $20 da $19 da Leerink Partners
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Il titolo di NeuroPace sale mentre UBS ribadisce il rating Buy dopo forti ricavi nel Q4
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
NeuroPace registra una crescita dei ricavi del 25% per il 2025, prevede crescita costante
NeuroPace reports 25% revenue growth for 2025, projects steady growth